Literature DB >> 799997

Comparative efficacy and safety of cephradine and cephalexin in children.

R Mouallem.   

Abstract

Cephradine was compared to cephalexin a randomized, double-blind study for the treatment of bacterial infections in 162 children between four months and eleven years of age. In addition to evaluations of clinical and bacteriologic responses to therapy, the relative safety of the two cephalosporins was assessed for all children, including eight who were not included in the evaluation of drug efficacy. The children in the efficacy evaluation had either lobar pneumonia or skin infections and received oral suspensions of cephradine (25-110 mg/kg per day) or cephalexin (25-150 mg/kg per day) for five to fifteen days. Overall clinical and bacteriologic responses were nearly identical in the two groups, and both antibiotics proved to equally safe and effective for use paediatric practice.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 799997     DOI: 10.1177/030006057600400409

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Antibiotics for community-acquired pneumonia in children.

Authors:  Rakesh Lodha; Sushil K Kabra; Ravindra M Pandey
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 4.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

5.  Development of Cephradine-Loaded Gelatin/Polyvinyl Alcohol Electrospun Nanofibers for Effective Diabetic Wound Healing: In-Vitro and In-Vivo Assessments.

Authors:  Anam Razzaq; Zaheer Ullah Khan; Aasim Saeed; Kiramat Ali Shah; Naveed Ullah Khan; Bouzid Menaa; Haroon Iqbal; Farid Menaa
Journal:  Pharmaceutics       Date:  2021-03-07       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.